Cardiovascular Eligibility Criteria and Adverse Event Reporting in Cancer Therapy Trials of Combined Immune Checkpoint and VEGF Inhibitors: A Systematic Review

Stephen Rankin, Benjamin Elyan, Robert Jones, Balaji Venugopal, Patrick B Mark, Jennifer S Lees, Mark C Petrie, Ninian N Lang
doi: https://doi.org/10.1101/2023.07.14.23292585

Data Availability

original data can be made available on request.

Back to top
Posted July 16, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Cardiovascular Eligibility Criteria and Adverse Event Reporting in Cancer Therapy Trials of Combined Immune Checkpoint and VEGF Inhibitors: A Systematic Review
Stephen Rankin, Benjamin Elyan, Robert Jones, Balaji Venugopal, Patrick B Mark, Jennifer S Lees, Mark C Petrie, Ninian N Lang
medRxiv 2023.07.14.23292585; doi: https://doi.org/10.1101/2023.07.14.23292585
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area